A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.

Jianjun Gao,Arlene Odelia Siefker-Radtke,Neema Navai,Matthew T. Campbell,Rebecca Slack,Charles Chuanhai Guo,Ashish M. Kamat,Surena F. Matin,John Papadopoulos,John C. Araujo,Amishi Yogesh Shah,Jorge Blando,Luis Vence,Fei Duan,Sreyashi Basu,Shalini Singh,Hao Zhao,Colin P. Dinney,Padmanee Sharma

A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.

2018

Jianjun Gao
Arlene Odelia Siefker-Radtke
Neema Navai
Matthew T. Campbell
Rebecca Slack
Charles Chuanhai Guo
Ashish M. Kamat
Surena F. Matin
John Papadopoulos
John C. Araujo
Amishi Yogesh Shah
Jorge Blando
Luis Vence
Fei Duan
Sreyashi Basu
Shalini Singh
Hao Zhao
Colin P. Dinney
Padmanee Sharma

e16524Background: In patients with muscle-invasive bladder cancer (MIBC), especially those with high risk features including lymphovascular invasion, hydronephrosis, T3b disease, or variant histolo...

Keywords:

Carcinoma
PD-L1
Cisplatin
Durvalumab
Physical therapy
Medicine
Tremelimumab
Cancer research
CTLA-4
Chemotherapy
Hydronephrosis
Bladder cancer
Lymphovascular invasion
Oncology
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations